Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast CancerHeikki Joensuu, Henrik Lindman, Päivi Auvinen et al.|JAMA Oncology|2018Cited by 149
Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendationsChristian F. Singer, D. Gareth Evans, Judith Balmañà et al.|European Journal of Cancer|2018Cited by 37